|

BCMA/GPRC5D CAR-T cells Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

  • Shenzhen University General Hospital1
  • Essen Biotech1

Indications

  • Multiple Myeloma in Relapse2
  • Cancer2
  • Multiple Myeloma Progression1
  • Multiple Myeloma, Refractory1
  • Multiple Myeloma1

Other2 trials

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1/2
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.